The global glaucoma treatment market is projected to grow from USD 5.7 billion in 2022 to USD 8.0 billion by 2033, at a CAGR ...

Advanced tools are being deployed by Duke Health and others in the fight against vision loss. STORY HIGHLIGHTS Half of ...

Bausch + Lomb announced the acquisition of the ELIOS system, a laser-based technology that offers a new approach to treating ...

Bausch + Lomb announced today that an affiliate acquired Elios Vision, developer of a minimally invasive glaucoma surgery ...

Bausch + Lomb Corporation (BLCO) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ...

Iantrek’s CREST Registry reports 1-year outcomes for a bio-interventional glaucoma treatment, demonstrating significant IOP reduction, medication reduction, and a favorable safety profile, offering a ...

ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced a research partnership with the John A.

Detailed price information for Bausch Lomb Corporation (BLCO-T) from The Globe and Mail including charting and trades.

The acquisition strengthens Bausch + Lomb's existing portfolio of surgical and pharmaceutical glaucoma treatments.